Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(4)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03594422Phase 1Recruiting

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Role: collaborator

NCT04126681Phase 2Completed

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Role: collaborator

NCT06640361Phase 3Recruiting

A Study of Olverembatinib in SDH-deficient GIST.

Role: collaborator

NCT03585322Phase 1Completed

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

Role: collaborator

NCT04126707Phase 1Completed

The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans

Role: collaborator

NCT03882281Phase 1Completed

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia

Role: collaborator

All 6 trials loaded